Exertional dyspnoea in COPD: The clinical utility of cardiopulmonary exercise testing

European Respiratory Review

Volumn 25, Issue 141, 2016, Pages 333-347

  O’Donnell, Denis E ^a   Elbehairy, Amany F ^a,b   Faisal, Azmy ^a,c   Webb, Katherine A ^a   Neder, J Alberto ^a   Mahler, Donald A ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c Alexandria University   (Egypt)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BICYCLE ERGOMETRY; BREATHING MUSCLE; CARDIOPULMONARY EXERCISE TEST; CHEMORECEPTOR REFLEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EXERTIONAL DYSPNEA; HUMAN; INSPIRATORY RESERVE VOLUME; LUNG ALVEOLUS OXYGEN TENSION; LUNG PERFUSION; LUNG VENTILATION; LUNG VOLUME; OXYGEN DESATURATION; PERSONALIZED MEDICINE; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY DRIVE; RESPIRATORY TRACT DISEASE ASSESSMENT; TOTAL LUNG CAPACITY; TREADMILL TEST; TREATMENT PLANNING; VISUAL ANALOG SCALE; BREATHING; COMPLICATION; EXERCISE; EXERCISE TEST; LUNG; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

DYSPNEA; EXERCISE; EXERCISE TEST; HUMANS; LUNG; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION; RESPIRATORY MUSCLES; RISK FACTORS;

EID: 84986206050     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0054-2016     Document Type: Article

References (142)

1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
2. Raghavan N, Lam Y-M, Webb KA, et al. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. COPD 2012; 9: 175-183.
3. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435-452.
4. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
5. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140: 331-342.
6. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
7. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004; 23: 28-33.
8. O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008; 15: Suppl. A, 1A-8A.
9. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2016. http://www.goldcopd.org Date last accessed: March 15, 2016.
10. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
11. Soumagne T, Laveneziana P, Veil-Picard M, et al. Asymptomatic subjects with airway obstruction have significant impairment at exercise. Thorax 2016; in press [DOI: 10.1136/thoraxjnl-2015-207953].
12. Oga T, Tsukino M, Hajiro T, et al. Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study. Respir Res 2012; 13: 85.
13. Lopes AJ, Mafort TT. Correlations between small airway function, ventilation distribution, and functional exercise capacity in COPD patients. Lung 2014; 192: 653-659.
14. Mahler DA, O’Donnell DE. Recent advances in dyspnea. Chest 2015; 147: 232-241.
15. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010; 137: 674-691.
16. O’Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007; 4: 145-168.
17. Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med 2016; 193: 299-309.
18. Caviedes IR, Delgado I, Soto R. Ventilatory inefficiency as a limiting factor for exercise in patients with COPD. Respir Care 2012; 57: 583-589.
19. Neder JA, Arbex FF, Alencar MC, et al. Exercise ventilatory inefficiency in mild to end-stage COPD. Eur Respir J 2015; 45: 377-387.
20. Elbehairy AF, Ciavaglia CE, Webb KA, et al. Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease. Implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med 2015; 191: 1384-1394.
21. Moreira MÂ, Medeiros GA, Boeno FP, et al. Oxygen desaturation during the six-minute walk test in COPD patients. J Bras Pneumol 2014; 40: 222-228.
22. Andrianopoulos V, Franssen FM, Peeters JP, et al. Exercise-induced oxygen desaturation in COPD patients without resting hypoxemia. Respir Physiol Neurobiol 2014; 190: 40-46.
23. Patessio A, Casaburi R, Carone M, et al. Comparison of gas exchange, lactate, and lactic acidosis thresholds in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 622-626.
24. Pleguezuelos E, Esquinas C, Moreno E, et al. Muscular dysfunction in COPD: systemic effect or deconditioning? Lung 2016; 194: 249-257.
25. O’Donnell DE, Laveneziana P, Webb K, et al. Chronic obstructive pulmonary disease: clinical integrative physiology. Clin Chest Med 2014; 35: 51-69.
26. Laveneziana P, Palange P, Ora J, et al. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. Eur J Appl Physiol 2009; 107: 633-643.
27. Laveneziana P, Valli G, Onorati P, et al. Effect of heliox on heart rate kinetics and dynamic hyperinflation during high-intensity exercise in COPD. Eur J Appl Physiol 2011; 111: 225-234.
28. Chiappa GR, Borghi-Silva A, Ferreira LF, et al. Kinetics of muscle deoxygenation are accelerated at the onset of heavy-intensity exercise in patients with COPD: relationship to central cardiovascular dynamics. J Appl Physiol (1985) 2008; 104: 1341-1350.
29. Vasilopoulou MK, Vogiatzis I, Nasis I, et al. On- and off-exercise kinetics of cardiac output in response to cycling and walking in COPD patients with GOLD Stages I-IV. Respir Physiol Neurobiol 2012; 181: 351-358.
30. Saey D, Debigaré R, Leblanc P, et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 425-430.
31. Gandevia SC. The perception of motor commands or effort during muscular paralysis. Brain 1982; 105: 151-159.
32. Gandevia SC, Killian KJ, Campbell EJ. The effect of respiratory muscle fatigue on respiratory sensations. Clin Sci 1981; 60: 463-466.
33. Guenette JA, Chin RC, Cheng S, et al. Mechanisms of exercise intolerance in global initiative for chronic obstructive lung disease grade 1 COPD. Eur Respir J 2014; 44: 1177-1187.
34. Jolley CJ, Luo YM, Steier J, et al. Neural respiratory drive and breathlessness in COPD. Eur Respir J 2015; 45: 355-364.
35. Potter WA, Olafsson S, Hyatt RE. Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. J Clin Invest 1971; 50: 910-919.
36. Dodd DS, Brancatisano TP, Engel LA. Effect of abdominal strapping on chest wall mechanics during exercise in patients with severe chronic air-flow obstruction. Am Rev Respir Dis 1985; 131: 816-821.
37. O’Donnell DE, Guenette JA, Maltais F, et al. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. Chest 2012; 141: 753-762.
38. Guenette JA, Chin RC, Cory JM, et al. Inspiratory capacity during exercise: measurement, analysis, and interpretation. Pulm Med 2013; 2013: 956081.
39. Killian KJ, Jones NL. Respiratory muscles and dyspnea. Clin Chest Med 1988; 9: 237-248.
40. Johnson BD, Weisman IM, Zeballos RJ, et al. Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. Chest 1999; 116: 488-503.
41. Dominelli PB, Foster GE, Guenette JA, et al. Quantifying the shape of the maximal expiratory flow-volume curve in mild COPD. Respir Physiol Neurobiol 2015; 219: 30-35.
42. Neder JA, O’Donnell CD, Cory J, et al. Ventilation distribution heterogeneity at rest as a marker of exercise impairment in mild-to-advanced COPD. COPD 2015; 12: 249-256.
43. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16: 269-275.
44. Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 622-629.
45. Chin RC, Guenette JA, Cheng S, et al. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2013; 187: 1315-1323.
46. Dempsey JA. Limits to ventilation (for sure!) and exercise (maybe?) in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 1282-1283.
47. Means JH. Dyspnoea, Medicine Monographs 3. Baltimore, Williams & Wilkins, 1924; pp. 309-416.
48. Elbehairy AF, Guenette JA, Faisal A, et al. Mechanisms of exertional dyspnoea in symptomatic smokers without COPD. Eur Respir J 2016; 48: 694-705.
49. Gandevia B, Hugh-Jones P. Terminology for measurements of ventilatory capacity. A report to the Thoracic Society. Thorax 1957; 12: 290-293.
50. Leblanc P, Summers E, Inman MD, et al. Inspiratory muscles during exercise: a problem of supply and demand. J Appl Physiol 1988; 64: 2482-2489.
51. O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.
52. Laveneziana P, Webb KA, Wadell K, et al. Does expiratory muscle activity influence dynamic hyperinflation and exertional dyspnea in COPD? Respir Physiol Neurobiol 2014; 199: 24-33.
53. Killian KJ, Gandevia SC, Summers E, et al. Effect of increased lung volume on perception of breathlessness, effort, and tension. J Appl Physiol 1984; 57: 686-691.
54. Chen Z, Eldridge FL, Wagner PG. Respiratory-associated thalamic activity is related to level of respiratory drive. Respir Physiol 1992; 90: 99-113.
55. O’Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 2006; 101: 1025-1035.
56. O’Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155: 109-115.
57. Laveneziana P, Webb KA, Ora J, et al. Evolution of dyspnea during exercise in COPD: impact of critical volume constraints. Am J Respir Crit Care Med 2011; 184: 1367-1373.
58. O’Donnell DE, Hong HH, Webb KA. Effects of chest wall restriction and deadspace loading on dyspnea and exercise tolerance in healthy normals. J Appl Physiol 2000; 88: 1859-1869.
59. Manning HL, Shea SA, Schwartzstein RM, et al. Reduced tidal volume increases ‘air hunger’ at fixed PCO2 in ventilated quadriplegics. Respir Physiol 1992; 90: 19-30.
60. Opie L, Smith A, Spalding J. Conscious appreciation of the effects produced by independent changes of ventilation volume and of end-tidal PCO2 in paralysed patients. J Physiol 1959; 149: 494-499.
61. Schwartzstein RM, Simon PM, Weiss JW, et al. Breathlessness induced by dissociation between ventilation and chemical drive. Am Rev Respir Dis 1989; 139: 1231-1237.
62. Eldridge F, Chen Z. Respiratory-associated rhythmic firing of midbrain neurons is modulated by vagal input. Respir Physiol 1992; 90: 31-46.
63. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J 2009; 33: 771-777.
64. Banzett RB, Pedersen SH, Schwartzstein RM, et al. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med 2008; 177: 1384-1390.
65. von Leupoldt A, Sommer T, Kegat S, et al. Dyspnea and pain share emotion-related brain network. Neuroimage 2009; 48: 200-206.
66. Davenport PW, Vovk A. Cortical and subcortical central neural pathways in respiratory sensations. Respir Physiol Neurobiol 2009; 167: 72-86.
67. von Leupoldt A, Dahme B. Cortical substrates for the perception of dyspnea. Chest 2005; 128: 345-354.
68. von Leupoldt A, Sommer T, Kegat S, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177: 1026-1032.
69. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002; 88: 1500-1511.
70. Pattinson K. Basic science for the chest physician: functional brain imaging in respiratory medicine. Thorax 2015; 70: 598-600.
71. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
72. Roig M, Eng JJ, MacIntyre DL, et al. Deficits in muscle strength, mass, quality, and mobility in people with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev 2011; 31: 120-124.
73. Ciavaglia CE, Guenette JA, Langer D, et al. Differences in respiratory muscle activity during cycling and walking do not influence dyspnea perception in obese patients with COPD. J Appl Physiol (1985) 2014; 117: 1292-1301.
74. Ciavaglia CE, Guenette JA, Ora J, et al. Does exercise test modality influence dyspnoea perception in obese patients with COPD? Eur Respir J 2014; 43: 1621-1630.
75. Ora J, Laveneziana P, Wadell K, et al. Effect of obesity on respiratory mechanics during rest and exercise in COPD. J Appl Physiol (1985) 2011; 111: 10-19.
76. O’Donnell DE, Ciavaglia CE, Neder JA. When obesity and chronic obstructive pulmonary disease collide. Physiological and clinical consequences. Ann Am Thorac Soc 2014; 11: 635-644.
77. Oliveira MF, Alencar MC, Arbex F, et al. Effects of heart failure on cerebral blood flow in COPD: rest and exercise. Respir Physiol Neurobiol 2016; 221: 41-48.
78. Arbex FF, Alencar MC, Souza A, et al. Exercise ventilation in COPD: influence of systolic heart failure. COPD 2016; in press [DOI: 10.1080/15412555.2016.1174985].
79. Oliveira MF, Zelt JT, Jones JH, et al. Does impaired O2 delivery during exercise accentuate central and peripheral fatigue in patients with coexistent COPD-CHF? Front Physiol 2014; 5: 514.
80. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381.
81. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989; 76: 277-282.
82. O’Donnell DE, Travers J, Webb KA, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J 2009; 34: 866-874.
83. Killian KJ, Summers E, Jones NL, et al. Dyspnea and leg effort during incremental cycle ergometry. Am Rev Respir Dis 1992; 145: 1339-1345.
84. Carrieri-Kohlman V, Gormley JM, Douglas MK, et al. Exercise training decreases dyspnea and the distress and anxiety associated with it. Monitoring alone may be as effective as coaching. Chest 1996; 110: 1526-1535.
85. Wadell K, Webb KA, Preston ME, et al. Impact of pulmonary rehabilitation on the major dimensions of dyspnea in COPD. COPD 2013; 10: 425-435.
86. Mahler DA, Gifford AH, Waterman LA, et al. Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest 2011; 140: 351-358.
87. Palange P, Forte S, Onorati P, et al. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol 2000; 88: 1715-1720.
88. Hsia D, Casaburi R, Pradhan A, et al. Physiological responses to linear treadmill and cycle ergometer exercise in COPD. Eur Respir J 2009; 34: 605-615.
89. Borel B, Provencher S, Saey D, et al. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med 2013; 2013: 410748.
90. Holm SM, Rodgers W, Haennel RG, et al. Effect of modality on cardiopulmonary exercise testing in male and female COPD patients. Respir Physiol Neurobiol 2014; 192: 30-38.
91. Sue DY, Wasserman K, Moricca RB, et al. Metabolic acidosis during exercise in patients with chronic obstructive pulmonary disease. Use of the V-slope method for anaerobic threshold determination. Chest 1988; 94: 931-938.
92. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167: 211-277.
93. Whipp BJ, Ward SA, Wasserman K. Ventilatory responses to exercise and their control in man. Am Rev Respir Dis 1984; 129: S17-S20.
94. Sun X-G, Hansen JE, Garatachea N, et al. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med 2002; 166: 1443-1448.
95. ERS Task Force, Palange P, Ward SA, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 2007; 29: 185-209.
96. Paoletti P, De Filippis F, Fraioli F, et al. Cardiopulmonary exercise testing (CPET) in pulmonary emphysema. Respir Physiol Neurobiol 2011; 179: 167-173.
97. Teopompi E, Tzani P, Aiello M, et al. Excess ventilation and ventilatory constraints during exercise in patients with chronic obstructive pulmonary disease. Respir Physiol Neurobiol 2014; 197: 9-14.
98. Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016; 374: 1811-1821.
99. Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015; 175: 1539-1549.
100. Furlanetto KC, Mantoani LC, Bisca G, et al. Reduction of physical activity in daily life and its determinants in smokers without airflow obstruction. Respirology 2014; 19: 369-375.
101. Elbehairy AF, Raghavan N, Cheng S, et al. Physiologic characterization of the chronic bronchitis phenotype in GOLD grade IB COPD. Chest 2015; 147: 1235-1245.
102. O’Donnell DE, D’Arsigny C, Fitzpatrick M, et al. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med 2002; 166: 663-668.
103. Peters MM, Webb KA, O’Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on dyspnea and exercise performance in normoxic COPD. Thorax 2006; 61: 559-567.
104. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016; 47: 429-460.
105. Neder JA, Jones PW, Nery LE, et al. Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. Am J Respir Crit Care Med 2000; 162: 497-504.
106. O’Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.
107. O’Donnell DE, Laveneziana P, Ora J, et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009; 64: 216-223.
108. Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 1351-1361.
109. Gagnon P, Saey D, Provencher S, et al. Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med 2012; 106: 1695-1705.
110. Mahler D, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014; 43: 1599-1609.
111. O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 2001; 18: 914-920.
112. Newton MF, O’Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050.
113. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
114. O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
115. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.
116. Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD 2010; 7: 428-437.
117. Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105: 580-587.
118. Verkindre C, Bart F, Aguilaniu B, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006; 73: 420-427.
119. Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
120. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
121. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012; 7: 503-513.
122. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991; 143: 9-18.
123. O’Donnell DE, McGuire M, Samis L, et al. Impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med 1995; 152: 2005-2013.
124. O’Donnell DE, McGuire M, Samis L, et al. Effects of general exercise training on ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. Am J Respir Crit Care Med 1998; 157: 1489-1497.
125. Lan CC, Chu WH, Yang MC, et al. Benefits of pulmonary rehabilitation in patients with COPD and normal exercise capacity. Respir Care 2013; 58: 1482-1488.
126. O’Donnell DE, D’Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 892-898.
127. O’Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med 1997; 155: 530-535.
128. Somfay A, Porszasz J, Lee SM, et al. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18: 77-84.
129. Uronis HE, Ekström MP, Currow DC, et al. Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. Thorax 2015; 70: 492-494.
130. Johnson M, Bland J, Oxberry S, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. Eur Respir J 2013; 42: 758-766.
131. Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage 2012; 43: 706-719.
132. Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015; 12: 1079-1092.
133. Rocker GM, Simpson AC, Young J, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes. CMAJ Open 2013; 1: E27-E36.
134. Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med 2013; 7: 123-134.
135. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol 2016; 81: 161-170.
136. Somfay A, Pórszász J, Lee SM, et al. Effect of hyperoxia on gas exchange and lactate kinetics following exercise onset in nonhypoxemic COPD patients. Chest 2002; 121: 393-400.
137. Dean NC, Brown JK, Himelman RB, et al. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis 1992; 146: 941-945.
138. Morrison DA, Stovall JR. Increased exercise capacity in hypoxemic patients after long-term oxygen therapy. Chest 1992; 102: 542-550.
139. Bye PT, Esau SA, Levy RD, et al. Ventilatory muscle function during exercise in air and oxygen in patients with chronic air-flow limitation. Am Rev Respir Dis 1985; 132: 236-240.
140. Criner GJ, Celli BR. Ventilatory muscle recruitment in exercise with O2 in obstructed patients with mild hypoxemia. J Appl Physiol 1987; 63: 195-200.
141. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
142. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010; 1: CD007354.